Germinal choice technology: Difference between revisions
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| Line 7: | Line 7: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{refbegin}} | {{refbegin}} | ||
Latest revision as of 17:50, 4 September 2012
Germinal choice technology refers to a set of reprogenetic technologies that, currently or that are expected to in the future, allow parents to influence the genetic constitutions of their children. This could be done through genetic screening of blastocysts (early embryos), or through germline engineering, which refers to human genetic engineering used to alter genes in the first cells of the blastocyst.[1]
Screening technologies have been in use since at least the mid 1990s to reduce the incidence of genetic disease, and what can be tested for is expected to become increasingly sophisticated in the late 2000s or early 2010's. Maturation in these fields would increase the range and sophistication of decisions open to parents. Germline engineering and even the engineering of human artificial chromosomes (which presently allow increased reliability) are presently being done in animals.
References
- Paul, Diane B. (2002). Swashbuckling into the Nebulous Future. American Scientist. (criticism)